98141-42-5

Usage

Uses

Used in Pharmaceutical Industry:
4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine is used as a potential antitumor agent for its capacity to target and treat cancer cells. Its antitumor properties are being studied for the development of cancer therapeutics, offering a new avenue for treatment options.
Used in Antiviral Applications:
In the field of virology, 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine is utilized for its potential antiviral activities, suggesting its use in the development of antiviral medications to combat viral infections.
Used in Drug Discovery:
4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine is employed as a candidate for the development of kinase inhibitors in drug discovery. Its inhibitory effects on various protein kinases make it a valuable compound for the creation of targeted therapies that can modulate cellular processes related to disease progression.

InChI:InChI=1/C6H4Cl2N4/c1-12-5-3(2-9-12)4(7)10-6(8)11-5/h2H,1H3

Upstream product

• 7339-53-9 methyl hydrazine hydrochloride 
• 50270-27-4 2,4,6-trichloropyrimidine-5-carbaldehyde 
• 302-15-8 methylhydrazine sulfuric acid 
• 42754-96-1 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 
• 74-88-4 methyl iodide 
• 5334-41-8 5-amino-4-cyano-1-methylpyrazole 
• 503-38-8 trichloromethyl chloroformate 
• 5401-15-0 1-Methyl-1H-pyrazolo<3,4-d>pyrimidine-4,6(5H,7H)-dione 
• 60-34-4 methylhydrazine 

Downstream Products

• 5413-96-7 6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1607479-47-9 C₂₂H₂₅N₉O 
• 100376-17-8 (6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-o-tolyl-amine 
• 5326-77-2 (6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-methyl-amine 
• 122568-11-0 N⁴,N⁶-bis-(2,4-dimethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diyldiamine 
• 30682-70-3 1-methylpyrazolo[3,4-d]pyrimidin-4,6(5H,7H)-dithione 
• 109042-48-0 ethyl-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-phenyl-amine 

Relevant academic research and scientific papers

PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof: (I), in which each of variables each of variables R, R1, R2, X1, X2, X3 and n is defined herein. Also disclosed is a method for treating a cancer with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant

The receptor tyrosine kinase rearranged during transfection (RET) plays pivotal roles in several cancers, including thyroid carcinoma and non-small cell lung cancer (NSCLC). Currently, there are several FDA-approved RET inhibitors, but their indication is limited to thyroid cancer, and none can overcome their gatekeeper mutants (V804L and V804M). Here, we report the discovery of 9x representing a new chemotype of potent and selective RET inhibitors, using a rational design strategy of type II kinase inhibitors. 9x exhibited both superior antiproliferative activities against NSCLC-related carcinogenic fusions KIF5B-RET and CCDC6-RET and gatekeeper mutant-transformed Ba/F3 cells, with the lowest GI50 of 9 nM, and substantial inhibitory activities against wild-type RET and RET mutant proteins, with the best IC50 of 4 nM. More importantly, 9x also showed nanomole potency against RET-positive NSCLC cells LC-2/ad, but not against a panel of RET-negative cancer cells, such as A549, H3122, A375 or parental Ba/F3 cells, demonstrating its selective ‘on-target’ effect. In mouse xenograft models, 9x repressed tumor growth driven by both wild type KIF5B-RET-Ba/F3 and gatekeeper mutant KIF5B-RET(V804M)-Ba/F3 cells in a dose-dependent manner. Together, these data establish that 9x provides a good starting point for the development of targeted therapeutics against RET-positive cancers, especially NSCLC.

SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF

A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF

A class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA

The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing influenza.

INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF

The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis

Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat.

PYRAZOLOPYRIMIDINE DERIVATIVES

Compounds of the formula (I), in which X, R1 and R2 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurode